Education
About Us
Working with TipRanks
Follow Us
Mesoblast Limited (AU:MSB)
:MSB
MSB Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.88 - AU$3.37
Previous CloseN/A
Volume5.54M
Average Volume (3M)5.76M
Market Cap
AU$2.21B
Enterprise ValueN/A
Total Cash (Recent Filing)AU$62.56M
Total Debt (Recent Filing)$118.92M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 28, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,277,782,200
10 Day Avg. Volume5,145,084
30 Day Avg. Volume5,758,173
Financial Highlights & Ratios
PEG Ratio-5.18
Price to Book (P/B)3.34
Price to Sales (P/S)0.00
P/FCF Ratio-75.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.90Price Target Upside67.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Mesoblast Limited News
PremiumCompany Announcements
Mesoblast Secures Seven-Year FDA Orphan-Drug Exclusivity for Ryoncil®
PremiumCompany Announcements
JPMorgan Acquires Substantial Stake in Mesoblast Limited
PremiumCompany Announcements
JPMorgan Ceases Substantial Holding in Mesoblast Limited
PremiumCompany Announcements
State Street Corporation Ceases Substantial Holding in Mesoblast Limited
PremiumCompany Announcements
Mesoblast Limited Announces New Substantial Holder
PremiumCompany Announcements
Mesoblast Limited Appoints New Director Lyn Cobley---
Options Prices
Currently, No data available
---
Ownership Overview
20.41% Insiders
2.45%
Mutual Funds
0.01% Other Institutional Investors
74.55% Public Companies and
Individual Investors
MSB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest share price was AU$0.88 and its highest was AU$3.37 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is AU$2.21B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is May 28, 2025 which is in 10 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 26, 2025. The company reported -AU$0.066 earnings per share for the quarter, missing the consensus estimate of -AU$0.044 by -AU$0.022.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is -0.02.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,277,782,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -AU$0.066 in its last earnings report, missing expectations of -AU$0.044. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in AU:MSB
---
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$2.90 (67.52% Upside)
AU$2.90 (67.52% Upside)
Blogger Sentiment
Bullish
AU:MSB Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $16.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.98%
12-Months-Change
Fundamentals
Return on Equity
-21.31%
Trailing 12-Months
Asset Growth
-2.53%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
---
MSB Company Deck
---
MSB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the FDA approval of a key product and successful fundraising, alongside a strategic pipeline expansion. However, financial losses and dependency on future regulatory approvals present challenges. Overall, the sentiment reflects a positive outlook with caution about future regulatory and financial hurdles.Read More>---
MSB Stock 12 Month Forecast
Average Price Target
AU$2.90
▲(67.52% Upside)
Technical Analysis
Biotron
―
Cochlear
―
Cynata Therapeutics Limited
―
Nanosonics Limited
―
Immutep Ltd
―
---